15-Hydroxy Fatty Acid Synthesis via Cysteine Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing 15-hydroxy fatty acid derivatives, such as 15-(S)-hydroxyeicosatrienoic acid (HETrE) and 15(S)-hydroxyeicosapentaenoic acid (HEPE), face challenges in scalability and cost-effectiveness, particularly in achieving high purity and yield, especially for clinical study programs, due to the use of sodium borohydride as a reducing agent which generates hydrogen gas and requires special handling, and the inconvenience of downstream processing with soy flour enzyme sources.
Innovation Solution
A two-step process involving enzymatic oxidation of fatty acids using lipoxygenase enzyme, followed by reduction with cysteine as a mild reducing agent under a pressurized oxygen atmosphere, allowing for in-situ reduction and simplifying purification, and utilizing soy flour as a cheaper enzyme source, reducing enzyme loadings and costs, and optimizing chromatography conditions for high-purity product generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium borohydride is used as a reducing agent, then reduction of hydroperoxide intermediate is achieved, but hydrogen gas is generated requiring special handling and increasing safety risks
Solution Approach 1:
The patent replaces sodium borohydride with cysteine as a reducing agent. Cysteine is a milder, safer reducing agent that does not generate hydrogen gas, eliminating the safety hazards associated with borohydride handling while effectively reducing the hydroperoxide intermediate to the desired hydroxy fatty acid derivative
Solution Approach 2:
The patent introduces an enzymatic oxidation step using lipoxygenase enzyme as an intermediary process. This enzyme-catalyzed oxidation converts the fatty acid to a hydroperoxide intermediate under controlled conditions, which is then reduced by cysteine. The enzyme acts as a mediator that enables selective oxidation without requiring harsh chemical oxidants
2Ease of manufacture
If soy flour enzyme source is used, then enzyme cost is reduced, but downstream processing becomes inconvenient
Solution Approach 1:
The patent utilizes soy flour as a cheap source of lipoxygenase enzyme, replacing expensive purified enzyme preparations. Although soy flour requires additional filtration steps, the significant cost reduction in enzyme material makes the overall process more economical, especially for large-scale production
Solution Approach 2:
The patent segments the enzyme source into a crude extract from soy flour rather than using purified enzyme. This allows the enzyme activity to be separated from the bulk soy flour material through filtration, enabling cost-effective enzyme supply while managing the complexity of downstream processing
3Productivity
If conventional production methods are used, then basic product formation is achieved, but scalability and cost-effectiveness for clinical study programs are limited
Solution Approach 1:
The patent optimizes reaction parameters including using pressurized oxygen atmosphere (greater than atmospheric pressure) to enhance oxygen solubility and reaction rate, controlling temperature to maintain enzyme activity, and adjusting pH to optimize both enzymatic oxidation and cysteine reduction efficiency. These parameter optimizations enable scalable production while maintaining high purity and yield
Solution Approach 2:
The patent implements a continuous two-step process where enzymatic oxidation and cysteine reduction are performed sequentially without isolating the hydroperoxide intermediate. This continuous flow approach minimizes handling steps, reduces contamination risks, and enables consistent quality suitable for clinical study materials
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process achieves high yields (>70%) of 15(S)-HETrE and 15(S)-HEPE with >95% purity, reduces enzyme and solvent costs, and simplifies downstream processing, making it suitable for multi-kilogram scale production conforming to cGMP standards, while avoiding hydrogen gas generation and enabling safer scale-up.
Implementation Method 1
The first step involves the enzymatic oxidation of the fatty acid to a 15(S)-hydroperoxide fatty acid intermediate (e.g., using a liquid enzyme formulation). The oxidation is under a pressurized oxygen atmosphere of at least 200 kPa (2 bar). In some embodiments, the enzymatic oxidation step includes contacting the fatty acid with lipoxygenase enzyme
Implementation Method 2
The oxidation is under a pressurized oxygen atmosphere of at least 200 kPa (2 bar)
Implementation Method 3
followed by reduction to the 15(S)-hydroxy fatty acid derivative using cysteine as a reducing agent. The step of reducing the 15(S)-hydroperoxy fatty acid intermediate comprises an in-situ reduction with cysteine
Implementation Method 4
In some embodiments, the isolating and/or purifying step comprises chromatography purification and/or crystallization
Implementation Method 5
In some embodiments, the isolating and/or purifying step comprises chromatography purification and/or crystallization
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides methods of making 15-hydroxy fatty acid derivatives, such as 15-(S)-hydroxyeicosatrienoic acid (HETrE or 15-(S)-HETrE) or 15(S)-hydroxyeicosapentaenoic acid (HEPE or 15(S)-HEPE) from the corresponding fatty acid (e.g., dihomo-Y-linolenic acid (DGLA) or eicosapentaenoic acid (EPA), respectively). In some embodiments, the method comprises contacting the fatty acid with an oxidizing agent (e.g., a lipoxygenase and oxygen) in the presence of a reducing agent (e.g., cysteine) to form the 15-hydroxy fatty acid derivatives in a single reaction vessel.